Remus Pharmaceuticals Limited
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
What Remus files
- Others54
- Investor Meet16
- Important11
- Board Meeting11
- Updates9
- Dividend/Bonus8
Remus Pharmaceuticals posted solid FY26 consolidated results. Revenue jumped 37.6% year-on-year to INR 853.6 Cr, with profit after tax (PAT) growing 20.2% to INR 46.2 Cr. Diluted EPS was also up 20.2% at INR 39.19. The company operates on an asset-light model, leveraging a diverse portfolio of 900+ products, with...
**1. Business Performance:** Remus Pharma's H1-FY26 revenue hit ₹400.2 Cr (+46.8% YoY), with PAT at ₹21.6 Cr (+20.9% YoY). Its asset-light model, focused on niche off-patent formulations, saw B2C revenue surge 6.3x YoY, reflecting strong global presence across 40+ semi-regulated markets. **2. Growth Drivers or Strategy:** Expanding its 800+ product...
Remus Pharma showcased robust FY25 performance, with consolidated revenue soaring ~191% to ₹620.4 Cr and profit after tax up ~58% to ₹38.4 Cr. Operating on an asset-light model, the company excels in niche, off-patent formulations across 40+ semi-regulated global markets. The 2024 acquisition of Espee Global Holdings marked a significant...
1. Financial Highlights: Remus Pharmaceuticals reported consolidated revenue of ₹620 Cr in FY25, up from ₹213 Cr in FY24. EBITDA grew to ₹50 Cr from ₹32 Cr, with standalone EBITDA margin improving marginally to 36.7%. PAT rose substantially to ₹38 Cr consolidated and ₹20 Cr standalone, indicating solid profitability growth....
**Financial Highlights:** For H1 FY 2025, Remus Pharmaceuticals reported consolidated total revenue of ₹27,555.54 lakhs, reflecting an increase from ₹30,69.90 lakhs in H1 FY 2024. Consolidated PAT surged to ₹1,401.12 lakhs, up from ₹564.76 lakhs in the prior year. Standalone revenue also rose to ₹4,021.23 lakhs, while PAT improved to...